Baxter to sell $500 million in debt
Baxter International Inc., the biggest maker of treatments for blood disorders, plans to sell $500 million of 10-year notes, according to a person familiar with the transaction.
The senior unsecured notes may price to yield about 110 basis points more than similar-maturity Treasuries, said the person, who declined to be identified because terms aren't set. A basis point is 0.01 percentage point.
The debt may be sold as soon as today, the person said.
The notes may be rated A3 by Moody's Investors Service and A+ by Standard & Poor's, the person said.
The Deerfield-based company hired Bank of America Corp., JPMorgan Chase & Co. and RBS Greenwich Capital to underwrite the sale, the person said.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.